Rebecca Hall Will Become Hikma Pharmaceuticals CFO in 2027
The current ViiV Healthcare finance chief will transition to the new executive role in the first quarter of 2027.
Updated on Sept. 24, 2026 in Healthcare
Hikma Pharmaceuticals will appoint Rebecca Hall as its new chief financial officer in the first quarter of 2027. Hall currently serves as the senior vice-president and chief financial officer at ViiV Healthcare.
Why it matters
The appointment marks a significant leadership transition for the pharmaceutical company as it plans to integrate Hall's extensive industry experience. She will join the board as an executive director upon her arrival, while Khalid Nabilsi transitions to a new leadership role within the firm.
Hall oversaw financial operations at ViiV Healthcare, which generated nearly £8 billion in 2025 revenue. She brings 14 years of prior experience from her tenure at GSK.
The players
Rebecca Hall
She is the incoming chief financial officer of Hikma Pharmaceuticals and former financial leader at ViiV Healthcare.
Hikma Pharmaceuticals
This multinational pharmaceutical company employs 9,500 people and maintains operations across North America, the Middle East, North Africa, and Europe.
Khalid Nabilsi
He is the outgoing chief financial officer of Hikma Pharmaceuticals who will transition to a deputy chief executive role.
ViiV Healthcare
This pharmaceutical company is majority-owned by GSK and specializes in HIV medicines.
Areb Kurdi
He currently serves as the acting chief financial officer at Hikma Pharmaceuticals.
The details
Rebecca Hall will succeed Khalid Nabilsi, who is stepping down from his current post on December 31, 2026, to become deputy chief executive for North America and Europe. Areb Kurdi will serve as the acting chief financial officer until Hall assumes her duties.
Timeline
In 2018, Rebecca Hall moved to ViiV Healthcare.
ViiV Healthcare generated nearly £8 billion in 2025 revenue.
Khalid Nabilsi steps down from the board on December 31, 2026.
Rebecca Hall joins Hikma Pharmaceuticals in the first quarter of 2027.
Market Landscape
This move highlights the ongoing movement of high-level financial leadership between established pharmaceutical entities like GSK and their affiliates. Such transitions are critical for companies as they aim to stabilize their financial oversight while expanding operations across global markets.
This leadership change is an internal corporate restructuring that does not immediately impact product pricing or consumer access to medicines. Customers and stakeholders should expect consistent operations as the company transitions its executive management team over the coming months.
The takeaway
Executive leadership transitions are common in the pharmaceutical industry as firms look to bring in experienced financial controllers to manage multi-billion pound revenue streams. Investors and observers should monitor how these shifts impact strategic growth in North American and European markets.
Further reading
Learn more about the latest leadership developments in the Healthcare sector.
